Cargando…
Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer
There is a high risk for bone loss and skeletal-related events, including bone metastases, in postmenopausal women with hormone receptor-positive breast cancer. Both the disease itself and its therapeutic treatments can negatively impact bone, resulting in decreases in bone mineral density and incre...
Autor principal: | Yardley, Denise A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4861000/ https://www.ncbi.nlm.nih.gov/pubmed/27217795 http://dx.doi.org/10.2147/BCTT.S97963 |
Ejemplares similares
-
A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases
por: Xu, Jing, et al.
Publicado: (2020) -
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
por: Lee, Su Jin, et al.
Publicado: (2011) -
Roles of Follicle-Stimulating Hormone on Bone Metabolism in Late Postmenopausal Women
por: Jeong, Chaiho, et al.
Publicado: (2022) -
Bone Density in Postmenopausal Women with or without Breast Arterial Calcification
por: Adibi, Atoosa, et al.
Publicado: (2017) -
Systematic review of the management of brain metastases from hormone receptor positive breast cancer
por: Jusino, Shirley, et al.
Publicado: (2023)